Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

BACKGROUND: Cough and sputum are troublesome symptoms in chronic obstructive pulmonary disease (COPD) and are associated with adverse outcomes. The efficacy of aclidinium bromide 400 µg twice daily in patients with stable COPD has been established in two phase III studies (ACCORD COPD I and ATTAIN)...

Descripción completa

Detalles Bibliográficos
Autores principales: McGarvey, Lorcan, Morice, Alyn H, Smith, Jaclyn A, Birring, Surinder S, Chuecos, Ferran, Seoane, Beatriz, Jarreta, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Chronic Obstructive Pulmonary Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174811/
https://www.ncbi.nlm.nih.gov/pubmed/28074135
http://dx.doi.org/10.1136/bmjresp-2016-000148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174811/
https://www.ncbi.nlm.nih.gov/pubmed/28074135
http://dx.doi.org/10.1136/bmjresp-2016-000148

Ejemplares similares